Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,392.00
Bid: 12,376.00
Ask: 12,380.00
Change: -74.00 (-0.59%)
Spread: 4.00 (0.032%)
Open: 12,466.00
High: 12,512.00
Low: 12,330.00
Prev. Close: 12,466.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

Tue, 21st May 2024 12:00

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

The FTSE 100 index opened down 29.22 points, 0.4%, at 8,394.98. The FTSE 250 was down 86.45 points, 0.4%, at 20,786.88. The AIM All-Share fell 2.67 points, 0.3%, at 807.27.

The Cboe UK 100 was down 0.4% at 837.74, the Cboe UK 250 was down 0.3%, trading at 18,205.17, and the Cboe Small Companies was up 0.1% at 16,554.39.

In European equities on Tuesday, the CAC 40 in Paris was down 1.0%, while the DAX 40 in Frankfurt fell 0.4%.

"European markets are in the red today, with concerns over the pathway to lower rates denting sentiment after a period of relative optimism," Scope Markets analyst Joshua Mahony commented.

"In a week that looks to be dominated by central bank appearances, the cautious approach taken by the Fed members Bostic and Mester did little to lift expectations over the September cut currently priced in by the markets. Today sees comments from the Bank of England Governor Bailey, who should set out his stall ahead of tomorrow's likely collapse in UK CPI inflation. With markets looking for headline inflation to fall back down towards the 2.3% region tomorrow, traders will be looking for Bailey to further shed light on the chance of a June rate cut given the wide disparity growing between headline and core inflation."

According to FXStreet cited consensus, the rate of annual consumer price inflation in the UK is expected to have declined to 2.1% in April, from 3.2% in March.

The International Monetary Fund said the UK economy is set for a "soft landing", and it urged the Bank of England to be mindful of rate cut timing.

The IMF said in a new report on the health of the UK economy that gross domestic product in the country is expected to grow by 0.7% for 2024, following 0.6% growth over the first quarter.

It represents an upgrade from the IMF's previous prediction of 0.5% growth for the year.

"As monetary policy reaches an inflection point, the timing and pace of rate cuts must carefully balance the risks of premature and delayed easing," the IMF cautioned Tuesday in its latest outlook document.

The pound was quoted at USD1.2717 early Tuesday afternoon in London, up from USD1.2702 at the time of the European equities close Monday. The euro stood at USD1.0866, up slightly from USD1.0862. Against the yen, the dollar was trading at JPY156.22, up from JPY156.14.

Stocks in New York are called to open largely flat. The Dow Jones Industrial Average and S&P 500 are called flat and the Nasdaq Composite down 0.1%.

Focus this week will be on earnings from chipmaker Nvidia, whose AI-driven stock market surge has been a key theme in recent months.

"The bar is high for Nvidia," XTB analyst Kathleen Brooks commented.

"The narrative ahead of the Nvidia results is that they will determine the fate of the AI stock market boom and the next leg higher for US stocks. However, while we think Nvidia's results are worth watching closely, the stock market rally has broadened out in recent weeks, so if Nvidia's results are a mild disappointment, we think the market should be able to recover."

In London, AstraZeneca was among the large-caps leading the way, rising 1.4%. It set out its ambition to achieve USD80 billion in annual revenue by the end of the decade, as it signalled a new "era of growth".

The target, which the Cambridge pharmaceuticals manufacturer firm described as "bold," would represent a 75% jump from the USD45.81 billion it achieved in 2023.

AstraZeneca said it would meet its aim by bolstering its oncology offering and rare disease portfolio, and launching 20 new treatments before the end of the decade.

Speaking ahead of an investor day, Chief Executive Officer Pascal Soriot said: "Today AstraZeneca announces a new era of growth. In 2023 we delivered the ambitious USD45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for USD80 billion by 2030. We are planning to launch 20 new medicines by 2030, many with the potential to generate more than USD5 billion in peak year revenues. The breadth of our portfolio together with continued investment in innovation supports sustained growth well past the end of the decade."

Reckitt rose 1.1%. The Financial Times reported activist Eminence Capital has built up a stake in the consumer goods firm.

Citing people familiar with the matter, the FT reported Eminence owns at least 0.5% of Reckitt's shares. It began buying in March, when the stock was hit by a verdict from an Illinois jury, which ordered Reckitt to pay USD60 million sum to the mother of a premature baby who died of an intestinal disease after being fed Enfamil baby formula.

Reckitt in March said it stands by the safety of its products. The company vowed to pursue all options to overturn the verdict.

Elsewhere in London, XP Power shares jumped 48% to 1,726 pence. The firm confirmed it rejected takeover approaches by New York-listed Advanced Energy Industries.

The maker of power control systems received approaches valuing it at GBP17 per share in October, at GBP18.50 in November and finally at GBP19.50 two weeks ago.

The latest proposal gives it an equity value of GBP468 million, and GBP571 million when including debt.

XP Power said the bids "fundamentally undervalues the company and its prospects".

Dowlais declined 6.6%, among the worst mid-cap performers. It cited foreign exchange headwinds and weakness in its ePowertrain business as it reported a drop in revenue in the first four months of 2024.

The automotive engineering spin-off of Melrose Industries, which listed in London back in April, was updating investors on trading ahead of Tuesday's annual general meeting.

In the four months to April 30, Dowlais said adjusted revenue fell 1.9% to GBP1.7 billion from the same period a year prior.

Revenue growth ahead of the market in Powder Metallurgy, Driveline3 and its China joint venture was more than offset by weakness in the ePowertrain4 product group of the Automotive business, Dowlais said.

Including foreign exchange headwinds of GBP90 million, adjusted revenue fell by 6.6%.

Overall, Dowlais described the start to the year as "broadly in line with expectations." The company anticipates revenue for 2024 will be slightly below the prior year at constant currency, with performance more weighted to the second half.

Gold was quoted at USD2,417.12 an ounce early Tuesday afternoon, down from USD2,423.50 late Monday afternoon. Brent oil was quoted at USD82.51 a barrel, falling from USD83.65.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.